Ignite Creation Date:
2025-12-24 @ 10:37 PM
Ignite Modification Date:
2026-01-02 @ 5:06 AM
Study NCT ID:
NCT01527435
Status:
COMPLETED
Last Update Posted:
2016-04-06
First Post:
2012-01-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)
Sponsor:
The Retina Center of St. Louis County, PC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-12
Start Date Type:
None
Primary Completion Date:
2015-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-12
Completion Date Type:
ACTUAL
First Submit Date:
2012-01-27
First Submit QC Date:
None
Study First Post Date:
2012-02-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-04-05
Last Update Post Date:
2016-04-06
Last Update Post Date Type:
ESTIMATED